Mechanisms of Resistance and Synergy: The Role of Tumor Microenvironment in HER2-Low Breast Cancer Therapy
HER2-low breast cancer, also known as IHC 1+ or IHC 2+ without ERBB2 amplification, is a new concept in the biology of breast cancer that has removed the binary classification of HER2-positive or HER2-negative breast cancer. The recent introduction of antibody-drug conjugates (ADCs), such as trastuz...
Sparad:
| Huvudupphov: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
MDPI AG
2026-03-01
|
| Serie: | Pharmaceuticals |
| Ämnen: | |
| Länkar: | https://www.mdpi.com/1424-8247/19/4/541 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|